Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors - Chen, Yu-Mu; Lai, Chien-Hao; Chang, Huang-Chih; Chao, Tung-Ying; Tseng, Chia-Cheng; Fang, Wen-Feng; Wang, Chin-Chou; Chung, Yu-Hsiu; Wang, Yi-Hsi; Su, Mao-Chang; Liu, Shih-Feng; Huang, Kuo-Tung; et al. (PloS one, 2016)
Keywords: Aged; Antacids; Antacids - therapeutic use; Antineoplastic Agents - therapeutic use; Biology and Life Sciences; Biopsy; Brain; Brain cancer; Brain Neoplasms - drug therapy; Brain Neoplasms - secondary; Brain research; Cancer; Cancer metastasis; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Care and treatment; Cerebrospinal fluid; Chemotherapy; Complications and side effects; Critical care; Development and progression; Dosage and administration; Drug interaction; Drug Interactions; Epidermal growth factor; Epidermal growth factor receptors; Female; Hospitals; Humans; Inhibitors; Internal medicine; Liver; Lung cancer; Lung diseases; Male; Medical prognosis; Medical research; Medicine; Medicine and Health Sciences; Metastases; Metastasis; Mutation; Nervous system; Non-small cell lung cancer; Non-small cell lung carcinoma; Oncology; Patients; Physicians; Prognosis; Protein Kinase Inhibitors - therapeutic use; Protein-tyrosine kinase receptors; Proton pump inhibitors; Receptor, Epidermal Growth Factor - antagonists & inhibitors; Research and Analysis Methods; Retrospective Studies; Risk factors; Survival; Tyrosine; Taiwan